

Testing and Isolation Efficacy: Insights from a Simple Epidemic Model

Ali Gharouni¹, F.M. Abdelmalek¹, Benjamin M. Bolker^{1,2,3}, Jonathan
Dushoff^{2,4,3}, and David J. D. Earn^{1,3,5}

¹Department of Mathematics & Statistics, McMaster University, Hamilton,
Canada

²Department of Biology, McMaster University, Hamilton, Canada

³Michael G. DeGroote Institute for Infectious Disease Research, McMaster
University, Hamilton, Canada

⁴South African Centre for Epidemiological Modelling and Analysis,
University of Stellenbosch, Stellenbosch, South Africa

July 7, 2021

1 Abstract

Testing individuals for pathogens can affect the spread of epidemics. Understanding how individual-level processes of sampling and reporting test results can affect community- or population-level spread is a dynamical modeling question. The effect of testing processes on epidemic dynamics depends on factors underlying implementation, particularly testing intensity and on whom testing is focused. Here, we use a simple model to explore how the individual-level effects of testing might directly impact population-level spread. Our model development was motivated by the COVID-19 epidemic, but has generic epidemiological and testing structures. To the classic SIR framework we have added a *per capita* testing intensity, and compartment-specific testing weights, which can be adjusted to reflect different testing emphases — surveillance, diagnosis, or control. We derive an analytic expression for the relative reduction in the basic reproductive number due to testing, test-reporting and related isolation behaviours. Intensive testing and fast test reporting are expected to be beneficial at the community level because they can provide a rapid assessment of the situation, identify hot spots, and may enable rapid contact-tracing. Direct effects of fast testing at the individual level are less clear, and may depend on how individuals' behaviour is affected by testing information. Our simple model shows that under some circumstances both increased testing intensity and faster test reporting can *reduce* the effectiveness of control, and allows us to explore the conditions under which this occurs. Conversely, we find that focusing testing on infected individuals always acts to increase effectiveness of control. **[DJDE: It would be**

21 *better to say “symptomatic” rather than “infected” in the last sentence, but we can’t claim*
22 *the model really captures that.]*

23 2 Introduction

24 The observed dynamics of the COVID-19 epidemic have been driven both by epidemiological
25 processes (infection and recovery) and by testing processes (testing and test reporting). In
26 addition to shaping epidemic observations (via case reports), testing processes also alter
27 epidemiological dynamics [Ali: (Peto, 2020; Taipale et al., 2020)]. Because individuals with
28 confirmed infections (positive tests) are likely to self-isolate, and individuals who are awaiting
29 the results of a test may also do so, testing will generally increase the number of people who
30 are isolating and hence reduce epidemic growth rates. We developed a mechanistic model
31 that incorporates epidemic processes and testing in order to explore the effects of testing
32 and isolation on epidemic dynamics.

33 If testing influences behavior, then epidemic dynamics will depend on who gets tested.
34 The impacts of testing will depend both on testing intensity (tests performed per day) and
35 on how strongly testing is focused on people who are infectious. This level of focus depends
36 in turn on the purpose and design of testing programs. When testing is done for the purposes
37 of disease surveillance (Foddai et al., 2020) tests are typically conducted randomly (or using
38 a stratified random design) across the population in order to make an unbiased assessment
39 of population prevalence.

40 Over the course of the COVID-19 pandemic, however, the vast majority of testing has
41 been done with other goals – primarily diagnostic (determining infection status for clinical
42 purposes)[Ali: (Phua et al., 2020; WHO, 2020)], or for control (determining infection status
43 in order to isolate cases that have been found by contact tracing) [Ali: (Aleta et al., 2020;
44 Kucharski et al., 2020; Grassly et al., 2020; Smith et al., 2020)], which we characterize
45 as *targeted* testing strategies. In these situations, testing probabilities can differ sharply
46 across epidemiological compartments; in our dynamical model, we will characterize these
47 probabilities by assigning a testing weight to each compartment that determines the *relative*
48 probability that an individual in that compartment will be selected for testing (see Methods).

49 Diagnostic testing focuses on people with infection-like symptoms; thus the relative test-
50 ing weights for infected people will depend on the relative probability of infected people
51 having symptoms. For COVID-19 infection, the testing weights will depend on the propor-
52 tion of asymptomatic infections, the time spent pre-symptomatic vs. symptomatic during
53 the course of an infection, and on the incidence of COVID-19-like symptoms among people in
54 the population *not* infected with COVID-19. Testing for epidemic control focuses on known
55 contacts of infected people; in this case the testing weights for infected vs. uninfected people
56 will depend on the probability of infection given contact, as well as the effectiveness of the
57 system for identifying suspicious contacts.

58 When a new infectious disease emerges, it is important to determine whether it will grow
59 exponentially in a susceptible population, and if so at what rate r (Ma et al., 2014). The
60 condition for positive exponential growth ($r > 0$) is commonly expressed as $\mathcal{R}_0 > 1$, where
61 the basic reproduction number \mathcal{R}_0 is the expected number of secondary infections arising
62 from a typical infective individual in a completely susceptible population (Dietz, 1993).

Although the value of \mathcal{R}_0 cannot completely characterize the dynamics of our model (Shaw and Kennedy, 2021), it does give a simple and widely accepted index for the difficulty of control, as well as an indication of the likely final size of an epidemic (Ma and Earn, 2006; Miller, 2012).

In order to understand the effect of testing processes on epidemic dynamics, we expanded one of the simplest mechanistic epidemic models—the standard deterministic SIR model (Kermack and McKendrick, 1927; Anderson and May, 1991)—to include testing components. This model provides a sensible platform to link the modeling of epidemic and testing components and study their interaction. We studied the effects of testing intensity, rate of test return, and isolation efficacy, on transmission probability and epidemic dynamics when different levels of testing focus (from random to highly targeted) are in place.

3 Methods

Our model groups individuals based on disease status (Susceptible, Infectious or Recovered) and testing status (*untested*, *waiting-for-positive*, *waiting-for-negative*, or *confirmed positive*) (Fig. 1). The testing status of an individual in a given disease compartment X (where $X \in \{S, I, R\}$) is denoted by a subscript, namely X_u , X_p , X_n and X_c , for *untested*, *waiting-for-positive*, *waiting-for-negative*, or *confirmed positive*, respectively. Two ‘accumulator’ compartments, N and P , are included in order to collect cumulative reported negative or positive tests. The model equations (A1) and details of calculation of the basic reproduction number \mathcal{R}_0 are presented in Appendix A.1.

Table 1 defines the model parameters, which are generally *per capita* flows between compartments, or modifiers to these flow rates. The novel component of the model lies in the compartment-specific relative testing weights w_S , w_I and w_R ; these give the relative rates at which people in the S , I , and R compartments are tested, respectively. Thus, we can specify different levels of testing focus from random (all weights equal) to highly targeted (higher weights in more intensively tested compartments). For example, $w_I/w_S = 3$ means that infected individuals are tested at three times the *per capita* rate of susceptible individuals.

In order to allow parameterization of the model by the total (overall) *per capita* testing rate, we define the weighted size of the testing pool $W = w_S S_u + w_I I_u + w_R R_u$, and calculate a scaling parameter for testing as:

$$\sigma = \frac{\rho N}{W}, \quad (1)$$

where ρ is the *per capita* testing intensity for the population, defined as the number of daily tests administered in a population of size N . Thus, the *per capita* testing rate for compartment $X \in \{S, I, R\}$ is

$$\mathcal{T}_X = \sigma w_X. \quad (2)$$

For a highly sensitive test, infected people typically flow through to the “confirmed positive” (I_c , R_c) compartments and are thus not considered for further testing. Over the course of the epidemic, a sufficiently large fixed testing rate as specified in (1) can exhaust the pool of people available for testing, leading to a singularity when too few people are left untested to support the specified rate. Although this phenomenon does not affect our analysis of \mathcal{R}_0 , it




Figure 1: Flowchart of the SIR (Susceptible-Infectious-Recovered) model, A1. The disease-based status of a compartment X ($X \in \{S, I, R\}$) is combined with the testing status including X_u , X_p , X_n and X_c , for *untested*, *waiting-for-positive*, *waiting-for-negative*, or *confirmed positive*, respectively. The force of infection is denoted by Λ (Eq. (3)); γ is the recovery rate; ω is the rate of test return; and τ_X (Eq. (2)) and p_X represent the *per capita* testing rate and the sensitivity (probability of positive tests), respectively, for compartment X . For further description of the parameters see Table 1. Note that there is a slight mismatch in the top-to-bottom order of the testing-based compartments of each disease-based compartment X between this flowchart and the model equations (A1); here we have switched X_u and X_n for visual clarity.

can affect model dynamics (we present an adjustment to the model that solves this problem in Appendix A.4).

The classical SIR model assumes a well-mixed population; homogeneity of the population (i.e., all individuals are equally susceptible and equally infectious with the same recovery rate when infected); exponentially distributed duration of infection; and large population size (Keeling and Rohani, 2011). In addition to these standard assumptions, our model assumes:

- (i) there is a single force of infection (new infections per unit time per susceptible), Λ , defined as

$$\Lambda = \frac{\beta}{N} (I_u + (1 - \theta_w)(I_n + I_p) + (1 - \theta_c)I_c), \quad (3)$$

with transmission rate β ; θ_w is the isolation efficacy (reduction of the probability of transmission) for individuals waiting for test results, while θ_c is the isolation efficacy for individuals who have received a “confirmed” positive test (Table 1). Susceptible individuals who are waiting for test results experience an additional transmission reduction factor of $1 - \theta_w$ (Fig. 1).

- (ii) confirmed-positive individuals isolate at least as effectively as those awaiting test results, i.e.,

$$0 \leq \theta_w \leq \theta_c \leq 1.$$

For simplicity we assume that tests are perfectly *specific* — uninfected individuals never test

positive ($p_s = 0$). Thus there are no waiting-for-positive or confirmed-positive susceptible individuals, which reduces the number of model states from 12 to 10.

Symbol	Description	Unit	Value
N	Total population size	people	10^6
ω	Rate of test return, i.e., rate of onward flow from “waiting” to “confirmed” or “untested” compartments	1/day	-
γ	Recovery rate	1/day	1/6
ρ	<i>per capita</i> testing intensity	1/day	-
θ_w	Isolation efficacy (reduction of the transmission probability) for “waiting” individuals	-	-
θ_c	Isolation efficacy for “confirmed positive” individuals	-	-
β	Transmission rate	1/day	0.5
Λ	Force of infection	1/day	-
p_S	Probability of positive tests for S ($= 1 - \text{specificity}$)	-	0
p_I	Probability of positive tests for I ($= \text{sensitivity}$)	-	1
p_R	Probability of positive tests for R ($= 1 - \text{specificity}$)	-	0.5
w_S, w_I, w_R	Relative testing weights	-	Random: $\{1, 1, 1\}$ Targeted: $\{0.3, 1, 1\}$

Table 1: Parameters of the model specified in (A1); see also Fig. 1.

The Disease-Free Equilibrium (DFE) for the expanded SIR model (Eqs. A1) is found by setting the infected compartments to 0 and solving for the unknowns. The DFE is

$$S_n^* = \frac{\rho}{\omega} N, \quad S_u^* = N - S_n^*, \quad \text{and} \quad I_j = R_j = 0 \quad \text{for all } j. \quad (4)$$

The corresponding *per capita* testing rate (Eq. 2) for the infected compartment I at DFE is one of the key analysis parameters and can be simplified as

$$\hat{\mathcal{T}}_I = (\omega\rho/(\omega - \rho))w_I/w_S \quad . \quad (5)$$

The basic reproduction number, \mathcal{R}_0 , was calculated by using the next-generation matrix method (van den Driessche and Watmough, 2002). We write \mathcal{R}_0 as

$$\mathcal{R}_0 = \frac{\beta}{\gamma} (1 - \Delta), \quad (6)$$

where β/γ is the classical value for a simple model (Keeling and Rohani, 2011), and $1 - \Delta$ is the proportional reduction due to testing and isolation processes. Δ therefore measures the “effectiveness of control”: how much these processes in reducing spread from low levels, and is in turn given by:

$$\Delta = \frac{1}{CN} (C_1 S_u^* + (C_2(1 - \theta_w) + C\theta_w) S_n^*), \quad (7)$$

where

$$C = (\omega + \gamma) \left(\gamma(\omega + \gamma) + (\gamma + \omega p_I) \hat{T}_I \right), \quad (8)$$

$$C_1 = (\omega + \gamma) (\theta_w \gamma + \theta_c \omega p_I) \hat{T}_I, \quad (9)$$

$$C_2 = \left(\omega \gamma (1 + p_I) \hat{T}_I + \gamma^2 (\omega + \gamma + \hat{T}_I) \right) \theta_w + \omega^2 p_I \hat{T}_I \theta_c. \quad (10)$$

(Appendix A.1 gives a detailed derivation of these expressions.) This explicit formula enables us to study the effects of testing and isolation parameters on \mathcal{R}_0 both analytically and via numerical solutions. We are specifically interested in parameters that could be manipulated by public health policy: isolation efficacy, θ_c and θ_w ; *per capita* testing intensity, ρ ; and the rate of test return, ω . In particular, we look at the partial derivatives of Δ with respect to these parameters (Appendix A.2). We derived general expressions for these derivatives. However, we analyzed the effect of ω on Δ for the special case of low testing intensity. Specifically, by making the restriction $\rho \ll 1$, we are able to Taylor-expand Δ at $\rho = 0$, use the linear approximation with respect to ρ and analyze the resulting simplified derivatives to illustrate a surprising non-monotonic relationship between Δ and ω .

Analytic calculation of the next-generation matrix and simplification of the \mathcal{R}_0 expression, were performed in Maple™ (Maple, 2010); numerical calculation and contour plots were done in R (R Core Team, 2020). We computed the values and contours of Δ at both low (Fig. 2) and high (Fig. 3) testing intensities, and for both random testing ($w_S = w_I = w_R = 1$) and targeted testing ($w_S = 0.3$; $w_I = w_R = 1$). Because it is expressed as a proportion of \mathcal{R}_0 , the effectiveness of control Δ is (at least in the $\rho \ll 1$ case, Eq. A23) independent of the transmission rate β , and hence of \mathcal{R}_0 in the case where we vary \mathcal{R}_0 by changing the transmission rate for a fixed generation interval.

The low-testing case Fig. 2 reflects the case where testing intensity ρ is small relative to the population size. Specifically, $\rho \in [0, 0.013]$, and test return rate $\omega \in [1/12, 2]$. This testing intensity is of the correct order of magnitude (although typically larger than) testing rates during the COVID-19 pandemic, i.e., a maximum of 1.3% of the population per day (approximately four times the maximum testing rate in Ontario, Canada in mid-2021). The less realistic high-testing case Fig. 3 is included to highlight the occurrence of non-monotonic changes in \mathcal{R}_0 with respect to ρ . In Fig. 3 the maximum capacity of ρ is larger relative to the population size, $\rho \in [0, 1/5)$ and the test return rate $\omega \in [1/5, 2]$; these values are clearly unrealistic for a large population but might be relevant for small populations undergoing focused testing, such as a sports league or university. In these figures, the implied baseline reproduction number (for the SIR model without testing) is $\mathcal{R}_0 = \frac{\beta}{\gamma} = 3$. The different ranges of test return rates ω for the cases of low and high testing intensities is due to the restriction $\rho < \omega$, which is a requirement for a feasible DFE (4).

4 Results

[JD: Should we talk less about \mathcal{R}_0 and keep the focus on Δ ? The back and forth is a bit tiring.] [Ali: unsure here, Help!] We can use the formula for \mathcal{R}_0 (6) to make a number of straightforward inferences about parameters that affect \mathcal{R}_0 monotonically, i.e., for which the associated partial derivative of Δ always has the same sign (see Appendices).

1. Increasing isolation efficacy for waiting (θ_w) and confirmed-positive (θ_c) individuals always decreases \mathcal{R}_0 (Eqs. A13, A16, A18);
2. Higher testing intensity ρ decreases \mathcal{R}_0 if testing is random (all w_X equal) or testing intensity (ρ) is small (Eq. A20).
3. Increasing the rate of test return (ω) always decreases \mathcal{R}_0 if waiting individuals do not isolate ($\theta_w = 0$) (Eq. A24).
4. Increasing testing focus, i.e., changing the testing weights from random ($w_S = w_I$) toward targeted ($w_S < w_I$), always decreases \mathcal{R}_0 (Eq. A28).




Figure 2: **Effectiveness of testing and isolation in reducing \mathcal{R}_0 at low *per capita* testing intensity (ρ).** Numerical evaluation of the effectiveness of control (Δ : eq. 7), over a range of testing and isolation parameters. Parameter values (Table 1): $\beta = 0.5/\text{day}$, $1/\gamma = 6.0$ days (baseline $\mathcal{R}_0 = 3.0$, $r = 0.3$); $\omega \in [1/12, 2]/\text{day}$; $\rho \in [0, 0.013]/\text{day per capita}$; θ_w and θ_c vary between 0 (no effect of isolation) and 1 (complete elimination of transmission); $p_S = 0$, $p_I = 1$ and $p_R = 0.5$. Only parameter sets where $\theta_c \geq \theta_w$ (confirmed-positive individuals isolate more effectively than waiting individuals) are shown; the alternative case, $\theta_w > \theta_c$, is unrealistic. Contours of Δ are plotted for (a) random testing ($w_S = w_I = w_R = 1$) and (b) targeted testing ($w_S = 0.3$; $w_I = w_R = 1$).

However, there are also two specific cases where Δ changes non-monotonically, in counterintuitive directions, as a function of testing and isolation parameters.

- We would generally expect increasing testing delays to increase \mathcal{R}_0 , thus decreasing effectiveness of control Δ . This is in fact what happens when waiting individuals do not isolate ($\theta_w = 0$, top row of Fig. 2) — as we move to the right within each plot in this row, Δ decreases. However, when waiting individuals isolate ($\theta_w > 0$), we more often see the opposite effect: longer testing delays lead to a greater control effect Δ (reduced \mathcal{R}_0). The reason is that people waiting for negative tests are assumed to continue to isolate; this applies both to susceptibles and to people who became infected while waiting for negative test results. This effect outweighs the effect of confirmed individuals isolating, except when this isolation parameter (θ_c) is substantially greater than θ_w . This result depends on the idea that, all else equal, people who have to wait longer for test results isolate at the same level (but for a longer time) as they would if the wait were shorter.
- Fig. 2 also shows that greater testing intensity (increasing ρ) generally increases the effectiveness of control (moving up in each panel). However, this relationship can




Figure 3: **Effectiveness of testing and isolation in reducing \mathcal{R}_0 at high *per capita* testing intensity.** Numerical evaluation of the effectiveness of control (Δ : eq. 7), over a range of testing and isolation parameters. Parameters as in Fig. 2 except: $\omega \in [1/5, 2]/\text{day}$, $\rho \in [0, 1/5]/\text{day}$. As in Fig. 2, subplots show (a) random testing where $w_S = w_I = w_R = 1$ and (b) targeted testing where $w_S = 0.3$ and $w_I = w_R = 1$.

be reversed at very high testing intensities (provided testing is targeted, and θ_w is relatively small; Fig. 3(b), right three panels of top row). It is theoretically possible for increasing testing intensity to *increase* \mathcal{R}_0 because more rapid testing leaves more susceptibles in the “waiting-for-negative-results” category at the DFE; if these people become infected while waiting, they will need to wait for their negative test result before they can be tested again, receive a positive test, and then begin self-isolating. This effect is usually weak compared to the beneficial effects of testing.

5 Discussion

[JD: Discuss the possibility that people who can’t get tests might also isolate. This undercuts our assumptions about θ_w .]

In this paper, we have developed and analyzed a simple compartmental model that combines epidemiological dynamics—as defined by a simple SIR model—with the dynamics of testing and isolation. Our model is a caricature: it models the most basic feedbacks between epidemic and testing processes, but does not attempt to incorporate the many known complications of COVID-19 epidemiology (e.g., exposed, pre-symptomatic, and asymptomatic compartments (Kain et al., 2021); time-varying testing rates [Ali: (Chin et al., 2020)]; behavioural dynamics (Weitz et al., 2020)). Thus, it is most appropriate for assessing the *qualitative* phenomena that arise from the interactions between transmission dynamics and

testing, rather than for making quantitative predictions or guiding pandemic responses.

Many of the qualitative results we have derived confirm simple, common-sense intuitions. In particular, we can generally decrease \mathcal{R}_0 by increasing isolation efficacy or testing intensity; returning tests faster, if individuals do not isolate while they are waiting for results; or increasing testing focus to target individuals who are likely to be infectious (e.g., symptomatic people or close contacts of known infections).

However, we did find two surprising patterns: longer delays in returning tests can *reduce* epidemic spread, and increasing testing rates can *increase* spread.

Over broad regions of parameter space, decreasing ω —i.e., *slowing* the rate at which test results are returned—*decreases* \mathcal{R}_0 (for random testing, the parameter region is $\theta_w \gtrsim 0.25$; for targeted testing, $\theta_w \geq 0.25$ and either $\theta_c \geq 0.5$ or $1/\omega > 5$; see Table 1 for parameter definitions). This result is counterintuitive and would not be expected by public health authorities that have invested a great deal of effort in reducing delays from testing to results. Dynamically, this effect occurs because speeding up test returns shortens the isolation period of uninfected individuals (for infected people it only shortens the time to progression to the isolation level of the confirmed-positive compartment). Slowing test returns increases \mathcal{R}_0 only if test positivity (the proportion of infectives in the tested population), and the magnitude of increase in isolation effectiveness from the waiting to the confirmed-positive compartment, are large enough to outweigh the decrease in isolation of uninfected waiting individuals. *[DJDE: That sentence is too long to process easily; I've re-organized slightly to make flow a bit better, but it is awkward to really fix it.]*

While slowing test returns does decrease \mathcal{R}_0 over broad regions of parameter space in our model, there are several real-world processes missing from our model that make it implausible that slowing test returns would actually be an effective public health measure. First, we do not model the primary benefit of rapid testing, i.e., detecting and containing outbreaks while they are still in progress. This process could be modeled phenomenologically by making the testing focus more targeted as an increasing proportion of cases is detected, because finding infections allows tests to be concentrated on their connections. Second, in the real world individuals become less likely to maintain isolation if they are required to do so for longer; phenomenologically, we could allow effectiveness of isolation while waiting for test returns to be an increasing function of test return speed, or we could introduce a separate “waiting, but no longer isolating” compartment that individuals entered from the “waiting, isolated” compartment at a specified rate. Third and finally, if one wants to decrease the overall transmission rate of the population there are more effective methods than keeping tested people in limbo; these include masking, ventilation, distancing measures, retail and event closures, and stay-at-home orders.

The other counterintuitive result from our analysis is that, for sufficiently high testing intensity ρ , further increasing testing intensity can actually *increase* \mathcal{R}_0 (e.g. Fig. 3(b), upper right panel [$\theta_c = 1$, $\theta_w = 0$]). This phenomenon occurs mainly because of a peculiar feature of the DFE in our model: we implicitly assume that testing is ongoing before the beginning of the epidemic, so that the starting point of the epidemic invasion is an equilibrium distribution of susceptibles between the S_n (untested) and S_u (waiting) compartments: in particular, $S_u^* = \rho/(\rho + \omega)$. (In reality, testing intensity itself is a dynamic variable that will increase as the epidemic proceeds.) If isolation in the waiting compartment is low ($\theta_w \ll 1$), then waiting individuals can easily be infected once the epidemic starts. Once infected they can

still infect others while in the waiting compartment, and cannot be tested again before they have returned to the untested compartment. Thus, under certain extreme conditions (low θ_w , high θ_c , low ω , high ρ), \mathcal{R}_0 becomes an increasing function of testing intensity. **[BMB: This phenomenon occurs primarily ([Ali: only]) for targeted testing, because ... CAN WE FIGURE OUT WHY? Targeting should be irrelevant to determining the DFE (because everyone is S at that point), so what is the dynamical explanation? Is there a second order effect somewhere, e.g. testing is more effective overall (darker colours in Fig 3(b) upper-right panel than in Fig 3(a) upper panel), so we more quickly reach the point where the effect of increasing S_n^* outweighs the beneficial effects of testing?]** However, this phenomenon is even more unrealistic than the possibility that slowing test returns increases \mathcal{R}_0 . It depends both on the assumption that regular testing is occurring before the epidemic starts, and on levels of testing that are unrealistically high (at least in large, general-population settings), i.e., at least 10% of the population being tested per day.

Although we model the testing process in more detail than typical epidemiological models, one place where more detail could be informative is in the processes determining the testing weights $\{w_S, w_I, w_R\}$. While random testing, as done for surveillance purposes, unambiguously leads to equal testing weights, making precise quantitative connections between public health practices and testing weights is difficult in other contexts. The testing weights reflect the correlation between an individual's risk of infection and their likelihood of being tested due to age, occupation, geographic location, etc.. This correlation is influenced, among many other factors, by the proportion of the uninfected population with COVID-like symptoms (e.g., due to seasonal upper respiratory tract infections); the concentration of transmission and testing in hot spots such as long-term care facilities and high-density workplaces; the overall testing intensity (and hence, e.g., restriction to symptomatic individuals); and the proportion of COVID-infected people who are symptomatic. Future steps should explore mathematically tractable ways to model some of these factors more precisely. For example, separating the infected class into exposed, symptomatic, and a- or pre-symptomatic compartments and allowing the testing weights to vary across non-symptomatic (exposed/asymptomatic/presymptomatic) vs. symptomatic compartments could reflect the allocation of tests for diagnostic purposes (targeting symptomatic individuals) vs. contact-tracing (targeting infected but non-symptomatic individuals) vs. screening (relatively equal weights, depending on the venue). Alternatively, one could make the testing weights depend on the testing intensity or test return rate as suggested above. Whatever complexity is added would probably put the model beyond reach of the analytical methods we have used in this paper, but one could still use semi-numerical methods such as constructing the next-generation matrix and using it to evaluate the derivatives of \mathcal{R}_0 with respect to the parameters numerically.

[DJDE: The intro and discussion would benefit from (potentially many) additional references.] Although testing and tracing is a key part of infection control strategies, mathematical epidemiologists have typically analyzed it with detailed models designed to inform particular public health efforts **[Ali: (Endo et al., 2020; Hellewell et al., 2020; Jenness et al., 2020)]**, rather than analyzing simple but general models of the feedback between testing and transmission dynamics. **[Ali: the following sentences added to address Ben's comment:]** There have been several modeling studies of testing and tracing dynamics and their interaction with epidemiological dynamics. In the context of repeated screening and random

testing of isolated populations (such as a university), Bergstrom et al. (2020) provided some analytical results which suggests, as an outbreak control strategy, that proactively screening asymptomatic individuals and isolating confirmed-positive cases would reduce the spread of the disease. In particular, They explored the effects of testing frequency and Trade-offs between frequency, accuracy and the reporting delay on the epidemic dynamic (more specifically, on the effective reproductive number). Rogers et al. (2021) simulated a SEIR model with testing and isolation which suggest a combination of rapid testing with antigen tests and the subsequent isolation of confirmed-positive individuals a strategy for controlling the disease dynamics in the COVID-19 pandemic. Further, Friston et al. (2021) model the effects of self-isolation on testing and tracing with the focused on posterior predictions and projections under different testing and tracing scenarios. They conclude that the emergence of a second wave depends almost exclusively on the rate at which immunity is lost and that it is necessary to track the 20% of asymptomatic individuals in order to control the outbreak. Our modeling approach is novel compared to these works as it mechanistically incorporates the epidemic and testing processes with different levels of testing focus from random to highly targeted. We hope that the present paper will inspire further explorations of the fundamental properties of epidemic models that incorporate explicit testing processes.

References

- Aleta, A., Martin-Corral, D., y Piontti, A. P., Ajelli, M., Litvinova, M., Chinazzi, M., Dean, N. E., Halloran, M. E., Longini Jr, I. M., Merler, S., et al. (2020). Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19. *Nature Human Behaviour*, 4(9):964–971.
- Anderson, R. M. and May, R. M. (1991). *Infectious Diseases of Humans: Dynamics and Control*. Oxford University Press, Oxford.
- Bergstrom, T., Bergstrom, C. T., and Li, H. (2020). Frequency and accuracy of proactive testing for COVID-19. *medRxiv*.
- Chin, E. T., Huynh, B. Q., Chapman, L. A., Murrill, M., Basu, S., and Lo, N. C. (2020). Frequency of routine testing for coronavirus disease 2019 (COVID-19) in high-risk healthcare environments to reduce outbreaks. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*.
- Dietz, K. (1993). The estimation of the basic reproduction number for infectious diseases. *Statistical methods in medical research*, 2(1):23–41.
- Endo, A., Leclerc, Q. J., Knight, G. M., Medley, G. F., Atkins, K. E., Funk, S., Kucharski, A. J., et al. (2020). Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreaks. *Wellcome Open Research*, 5(239):239.
- Foddai, A., Lubroth, J., and Ellis-Iversen, J. (2020). Base protocol for real time active random surveillance of coronavirus disease (COVID-19)—adapting veterinary methodology to public health. *One Health*, page 100129.

- Friston, K. J., Parr, T., Zeidman, P., Razi, A., Flandin, G., Daunizeau, J., Hulme, O. J., Billig, A. J., Litvak, V., Price, C. J., et al. (2021). Testing and tracking in the UK: A dynamic causal modelling study. *Wellcome Open Research*, 5:144.
- Grassly, N. C., Pons-Salort, M., Parker, E. P., White, P. J., Ferguson, N. M., Ainslie, K., Baguelin, M., Bhatt, S., Boonyasiri, A., Brazeau, N., et al. (2020). Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study. *The Lancet Infectious Diseases*, 20(12):1381–1389.
- Hellewell, J., Abbott, S., Gimma, A., Bosse, N. I., Jarvis, C. I., Russell, T. W., Munday, J. D., Kucharski, A. J., Edmunds, W. J., Sun, F., et al. (2020). Feasibility of controlling covid-19 outbreaks by isolation of cases and contacts. *The Lancet Global Health*, 8(4):e488–e496.
- Jenness, S. M., Willebrand, K. S., Malik, A. A., Lopman, B. A., and Omer, S. B. (2020). Modeling dynamic network strategies for SARS-CoV-2 control on a cruise ship. *medRxiv*.
- Kain, M. P., Childs, M. L., Becker, A. D., and Mordecai, E. A. (2021). Chopping the tail: How preventing superspreading can help to maintain COVID-19 control. *Epidemics*, 34:100430.
- Keeling, M. J. and Rohani, P. (2011). *Modeling infectious diseases in humans and animals*. Princeton University Press.
- Kermack, W. O. and McKendrick, A. G. (1927). A contribution to the mathematical theory of epidemics. *Proceedings of the Royal Society of London Series A*, 115:700–721.
- Kucharski, A. J., Klepac, P., Conlan, A. J., Kissler, S. M., Tang, M. L., Fry, H., Gog, J. R., Edmunds, W. J., Emery, J. C., Medley, G., et al. (2020). Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of sars-cov-2 in different settings: a mathematical modelling study. *The Lancet Infectious Diseases*, 20(10):1151–1160.
- Ma, J., Dushoff, J., Bolker, B. M., and Earn, D. J. D. (2014). Estimating initial epidemic growth rates. *Bulletin of mathematical biology*, 76(1):245–260.
- Ma, J. and Earn, D. J. D. (2006). Generality of the final size formula for an epidemic of a newly invading infectious disease. *Bulletin of Mathematical Biology*, 68(3):679–702.
- Maple (2010). Maplesoft, a division of Waterloo Maple Inc., Waterloo, Ontario. Version 14.
- Miller, J. C. (2012). A note on the derivation of epidemic final sizes. *Bulletin of mathematical biology*, 74(9):2125–2141.
- Peto, J. (2020). Covid-19 mass testing facilities could end the epidemic rapidly. *Bmj*, 368.
- Phua, J., Weng, L., Ling, L., Egi, M., Lim, C.-M., Divatia, J. V., Shrestha, B. R., Arabi, Y. M., Ng, J., Gomersall, C. D., et al. (2020). Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. *The Lancet Respiratory Medicine*, 8(5):506–517.

370 R Core Team (2020). *R: A Language and Environment for Statistical Computing*. R Foun-
371 dation for Statistical Computing, Vienna, Austria.

372 Rogers, W., Ruiz-Aravena, M., Hansen, D., Sonoma, W. M., Kessler, M., Fields, M. W.,
373 Ferrari, M. J., Chang, C. B., Morrow, J., Hoegh, A., et al. (2021). High-frequency screening
374 combined with diagnostic testing for control of SARS-CoV-2 in high-density settings: an
375 economic evaluation of resources allocation for public health benefit. *medRxiv*.

376 Shaw, C. L. and Kennedy, D. A. (2021). What the reproductive number R_0 can and cannot
377 tell us about COVID-19 dynamics. *Theoretical Population Biology*.

378 Smith, L. E., Potts, H. W., Amlot, R., Fear, N. T., Michie, S., and Rubin, J. (2020).
379 Adherence to the test, trace and isolate system: results from a time series of 21 nationally
380 representative surveys in the UK (the COVID-19 rapid survey of adherence to interventions
381 and responses [CORSAIR] study). *MedRxiv*.

382 Taipale, J., Romer, P., and Linnarsson, S. (2020). Population-scale testing can suppress the
383 spread of COVID-19. *MedRxiv*.

384 van den Driessche, P. and Watmough, J. (2002). Reproduction numbers and sub-threshold
385 endemic equilibria for compartmental models of disease transmission. *Mathematical bio-*
386 *sciences*, 180(1-2):29–48.

387 Weitz, J. S., Park, S. W., Eksin, C., and Dushoff, J. (2020). Awareness-driven behavior
388 changes can shift the shape of epidemics away from peaks and toward plateaus, shoulders,
389 and oscillations. *Proceedings of the National Academy of Sciences*, 117(51):32764–32771.

390 WHO (2020). Global surveillance for COVID-19 caused by human infection with COVID-19
391 virus: interim guidance.

A Appendix

A.1 Model and calculation of \mathcal{R}_0

The model in the form of a system of ordinary differential equations is

$$dS_u/dt = -\Lambda S_u - \mathcal{T}_S S_u + \omega S_n, \quad (\text{A1a})$$

$$dS_n/dt = -(1 - \theta_w)\Lambda S_n + (1 - p_S)\mathcal{T}_S S_u - \omega S_n, \quad (\text{A1b})$$

$$dS_p/dt = -(1 - \theta_w)\Lambda S_p + p_S \mathcal{T}_S S_u - \omega S_p, \quad (\text{A1c})$$

$$dS_c/dt = -(1 - \theta_c)\Lambda S_c + \omega S_p, \quad (\text{A1d})$$

$$dI_u/dt = \Lambda S_u - \mathcal{T}_I I_u + \omega I_n - \gamma I_u, \quad (\text{A1e})$$

$$dI_n/dt = (1 - \theta_w)\Lambda S_n + (1 - p_I)\mathcal{T}_I I_u - \omega I_n - \gamma I_n, \quad (\text{A1f})$$

$$dI_p/dt = (1 - \theta_w)\Lambda S_p + p_I \mathcal{T}_I I_u - \omega I_p - \gamma I_p, \quad (\text{A1g})$$

$$dI_c/dt = (1 - \theta_c)\Lambda S_c + \omega I_p - \gamma I_c, \quad (\text{A1h})$$

$$dR_u/dt = \gamma I_u - \mathcal{T}_R R_u + \omega R_n, \quad (\text{A1i})$$

$$dR_n/dt = \gamma I_n + (1 - p_R)\mathcal{T}_R R_u - \omega R_n, \quad (\text{A1j})$$

$$dR_p/dt = \gamma I_p + p_R \mathcal{T}_R R_u - \omega R_p, \quad (\text{A1k})$$

$$dR_c/dt = \gamma I_c + \omega R_p, \quad (\text{A1l})$$

$$dN/dt = \omega(S_n + I_n + R_n), \quad (\text{A1m})$$

$$dP/dt = \omega(I_p + R_p), \quad (\text{A1n})$$

(see Table 1 for parameter definitions). The next generation matrix for this model is $G = FV^{-1}$, where matrix F represents the inflow of new infection to the infected compartments and matrix V represents the flow in the infected compartments when the population is totally susceptible. Matrices F and V are **[BMB: eqs A2 and A3 can be in the same array environment, but sticking the “and” in there is ugly. “and” should be in text, with A4 set as a separate equation (it doesn’t need to be aligned).]**

$$F = \beta/N \begin{bmatrix} S_u^* & (1 - \theta_w)S_u^* & (1 - \theta_w)S_u^* & (1 - \theta_c)S_u^* \\ (1 - \theta_w)S_n^* & (1 - \theta_w)^2 S_n^* & (1 - \theta_w)^2 S_n^* & (1 - \theta_w)(1 - \theta_c)S_n^* \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \end{bmatrix} \quad (\text{A2})$$

$$= \beta/N \begin{bmatrix} S_u^* \\ (1 - \theta_w)S_n^* \\ 0 \\ 0 \end{bmatrix} [1, 1 - \theta_w, 1 - \theta_w, 1 - \theta_c], \text{ and} \quad (\text{A3})$$

$$V = \begin{bmatrix} \hat{\mathcal{T}}_I + \gamma & -\omega & 0 & 0 \\ -(1 - p_I)\hat{\mathcal{T}}_I & \omega + \gamma & 0 & 0 \\ -p_I \hat{\mathcal{T}}_I & 0 & \omega + \gamma & 0 \\ 0 & 0 & -\omega & \gamma \end{bmatrix}. \quad (\text{A4})$$

The matrix inverse of V is

$$V^{-1} = \frac{1}{\gamma C} \begin{bmatrix} \gamma(\omega + \gamma)^2 & \gamma\omega(\omega + \gamma) & 0 & 0 \\ \gamma(\omega + \gamma)(1 - p_I)\hat{\mathcal{T}}_I & \gamma(\omega + \gamma)(\hat{\mathcal{T}}_I + \gamma) & 0 & 0 \\ \gamma(\omega + \gamma)p_I\hat{\mathcal{T}}_I & \gamma\omega p_I\hat{\mathcal{T}}_I & C\gamma/(\omega + \gamma) & 0 \\ \omega(\omega + \gamma)p_I\hat{\mathcal{T}}_I & \omega^2 p_I\hat{\mathcal{T}}_I & C\omega/(\omega + \gamma) & C \end{bmatrix}, \quad (\text{A5})$$

where $C = (\gamma(\omega + \gamma) + (\gamma + \omega p_I)\hat{\mathcal{T}}_I)(\omega + \gamma)$ and $\hat{\mathcal{T}}_I$ is the *per capita* testing rate for the infected people and represented in Eq. (5). Note that all the columns of matrix V^{-1} sum up to $1/\gamma$.

The particular form of F with two rows of zeros at the bottom results in the following blocked form of matrix G .

$$G = \begin{bmatrix} G_{11} & G_{12} \\ 0 & 0 \end{bmatrix}, \quad (\text{A6})$$

where both blocked matrices G_{11} and G_{12} are 2 by 2. Given the upper triangular form of matrix G , the basic reproduction number \mathcal{R}_0 (defined as the spectral radius of matrix G) is only determined by the blocked matrix G_{11} ,

$$G_{11} = \frac{\beta}{\gamma C} \begin{bmatrix} (\omega - \rho)/\omega \\ (1 - \theta_w)\rho/\omega \end{bmatrix} \begin{bmatrix} 1, 1 - \theta_w, 1 - \theta_w, 1 - \theta_c \end{bmatrix} \begin{bmatrix} \gamma(\omega + \gamma)^2 & \gamma\omega(\omega + \gamma) \\ \gamma(\omega + \gamma)(1 - p_I)\hat{\mathcal{T}}_I & \gamma(\omega + \gamma)(\hat{\mathcal{T}}_I + \gamma) \\ \gamma(\omega + \gamma)p_I\hat{\mathcal{T}}_I & \gamma\omega p_I\hat{\mathcal{T}}_I \\ \omega(\omega + \gamma)p_I\hat{\mathcal{T}}_I & \omega^2 p_I\hat{\mathcal{T}}_I \end{bmatrix}. \quad (\text{A7})$$

It is notable that matrix F (A2) has rank one and consequently G_{11} does so. That is G_{11} has only one non-zero eigenvalue which is \mathcal{R}_0 .

The expression of \mathcal{R}_0 has a complicated form with all of the model parameters involved. This expression can be simplified and represented given the specific form of matrix G_{11} (A7). For the purpose of simplicity we present \mathcal{R}_0 in the manuscript in terms of expressions C , C_1 and C_2 , specified in (8).

It remains hard to show that the reproduction number \mathcal{R}_0 is decreasing with respect to *per capita* testing intensity, ρ , and the speed of the test return, ω , for the feasible ranges of the parameters, that is

$$\omega > 0, \quad (\text{A8})$$

$$0 \leq \rho < \omega, \quad (\text{A9})$$

$$0 \leq \theta_w \leq \theta_c \leq 1, \quad (\text{A10})$$

$$\frac{w_I}{w_S} \geq 1. \quad (\text{A11})$$

In realistic cases the testing rate ρ is very small (i.e., only a small fraction of the population can be tested every day); it is thus reasonable to use a linear approximation of \mathcal{R}_0 for $\rho \ll 1$ to analyze the behaviour of \mathcal{R}_0 with respect to ω (see section Appendix A.3). In the next section we provide an equivalent representation of \mathcal{R}_0 in order to show that increasing testing intensity typically decreases \mathcal{R}_0 .

A.2 More testing intensity may decrease \mathcal{R}_0

This section shows that $\frac{\partial \Delta}{\partial \rho}$ can be positive or negative, with Δ defined in Eq. (8), and thus $\frac{\partial \mathcal{R}_0}{\partial \rho} < 0$, where \mathcal{R}_0 is given in Eq. (6). We rewrite matrix G_{11} in (A7) in the following form to simplify the calculations:

$$G_{11} = \frac{\beta}{\gamma C} \begin{bmatrix} S_u^*/N \\ (1 - \theta_w)S_n^*/N \end{bmatrix} [C - C_1, C - C_2], \quad (\text{A12})$$

where C is the same as the one in Eq. (8), i.e.,

$$C = (\omega + \gamma)(\gamma(\omega + \gamma) + (\omega p_I + \gamma)\hat{\mathcal{T}}_I),$$

and C_1 and C_2 are

$$\begin{aligned} C_1 &= (\omega + \gamma)(\theta_w \gamma + \theta_c \omega p_I) \hat{\mathcal{T}}_I, \\ C_2 &= (\omega \gamma (1 + p_I) \hat{\mathcal{T}}_I + \gamma^2 (\omega + \gamma + \hat{\mathcal{T}}_I)) \theta_w + \omega^2 p_I \hat{\mathcal{T}}_I \theta_c, \end{aligned}$$

where $\hat{\mathcal{T}}_I$ is given in Eq. (5). Note that for analysis brevity, we let $N = 1$, thus S_u^* and S_n^* are in the scale of 0 to 1. \mathcal{R}_0 is in the same form as in Eq. (6)

$$\mathcal{R}_0 = \frac{\beta}{\gamma} (1 - \Delta),$$

where

$$\Delta = \frac{1}{C} (C_1 S_u^* + (C_2 (1 - \theta_w) + C \theta_w) S_n^*).$$

The first goal is to explore how changes in isolation, θ_w and θ_c , affects \mathcal{R}_0 . Mathematically we would like to verify the sign of $\frac{\partial \mathcal{R}_0}{\partial \theta_w}$ and $\frac{\partial \mathcal{R}_0}{\partial \theta_c}$. We start with simplifying Δ (A.2) by factoring θ_w and θ_c in Eq. (A.2). Thus, Δ can be rewritten as

$$\Delta = \frac{1}{C} \left(-D_1 S_n^* \theta_w^2 + (-\omega^2 p_I \hat{\mathcal{T}}_I S_n^* \theta_c + D_2 S_n^* + \gamma \hat{\mathcal{T}}_I (\omega + \gamma)) \theta_w + (\omega + \gamma S_u^*) \omega p_I \hat{\mathcal{T}}_I \theta_c \right), \quad (\text{A13})$$

where

$$D_1 = (\omega + \gamma) \gamma^2 + (\omega + \gamma + \omega p_I) \gamma \hat{\mathcal{T}}_I, \quad (\text{A14})$$

$$D_2 = (3\omega + 2\gamma) \gamma^2 + (\omega + \gamma + 2\omega p_I) \gamma \hat{\mathcal{T}}_I + (\gamma + p_I \hat{\mathcal{T}}_I) \omega^2. \quad (\text{A15})$$

Δ , Eq. (A13), is linear in θ_c with a positive coefficient. thus

$$\frac{\partial \Delta}{\partial \theta_c} = 1/C (\gamma S_u^* + \omega (1 - \theta_w S_n^*)) \omega p_I \hat{\mathcal{T}}_I. \quad (\text{A16})$$

This results in increasing Δ , thus decreasing \mathcal{R}_0 with respect to θ_c , that is $\frac{\partial \mathcal{R}_0}{\partial \theta_c} \leq 0$. Note that C is independent of θ_c and θ_w .

With a similar logic, Δ (A13) is a concave-down quadratic equation in θ_w , given by

$$1/C \left(-D_1 S_n^* \theta_w^2 + (-\omega^2 p_I \hat{\mathcal{T}}_I S_n^* \theta_c + D_2 S_n^* + \gamma \hat{\mathcal{T}}_I (\omega + \gamma)) \theta_w \right). \quad (\text{A17})$$

We show that the feasible range of θ_w lies between 0 and the vertex of this parabola where the parabola is increasing in θ_w , and so does Δ which results in inferring $\frac{\partial \mathcal{R}_0}{\partial \theta_w} \leq 0$. It is enough to show that partial derivative of the expression (A17) with respect to θ_w at $\theta_w = 1$ is non-negative. It follows that

$$\begin{aligned} \left. \frac{\partial \Delta}{\partial \theta_w} \right|_{\theta_w=1} &= 1/C \left((D_2 - 2D_1 - \omega^2 p_I \hat{T}_I \theta_c) S_n^* + \gamma \hat{T}_I (\omega + \gamma) \right) \\ &= 1/C \left((\gamma(\omega + \gamma) + \gamma\omega^2 + (1 - \theta_c)\omega^2 p_I \hat{T}_I) S_n^* + \gamma(\omega + \gamma) \hat{T}_I (1 - S_n^*) \right), \end{aligned} \quad (\text{A18})$$

which is a positive quantity, given that θ_c and S_n^* vary between 0 and 1.

The second goal is to explore how changes in *per capita* testing intensity ρ affects \mathcal{R}_0 . Mathematically we would like to verify the sign of $\frac{\partial \mathcal{R}_0}{\partial \rho}$, which specifically depends on $\frac{\partial \Delta}{\partial \rho}$. We use the derived expressions for S_u^* and S_n^* , given by Eqs. (4), in Δ (A.2). Also, we define $\phi = \hat{T}_S = \frac{\rho\omega}{\omega - \rho}$, to reparameterize ρ . This is mainly to avoid singularity in \hat{T}_I (5), when testing intensity ρ is very close to the rate of test return ω . Thus, ρ is reparameterized as

$$\rho = \frac{\omega\phi}{\omega + \phi}. \quad (\text{A19})$$

This one-to-one monotonic reparameterization enables us to simplify the mathematical expressions and explore the simpler $\frac{\partial \Delta}{\partial \phi}$ instead of the complicated $\frac{\partial \Delta}{\partial \rho}$. The derivative is

$$\partial \Delta / \partial \phi = \frac{1}{d_3} (a_3 \phi^2 + b_3 \phi + c_3), \quad (\text{A20})$$

where

$$\begin{aligned} a_3 &= \frac{w_I}{w_S} \left((1 - \theta_w) \left(1 + \frac{w_I}{w_S} \right) \theta_w \gamma^3 + (1 - \theta_c) p_I^2 \theta_w \frac{w_I}{w_S} \omega^3 \right. \\ &\quad + \left(\left((1 - \theta_w - \frac{w_I}{w_S}) \theta_c + (3 - 2\theta_w) \theta_w \frac{w_I}{w_S} \right) p_I + (1 - \theta_w) \left(1 + \frac{w_I}{w_S} \right) \theta_w \right) \omega \gamma^2 \\ &\quad \left. + \left(\left((1 - \theta_w - \theta_w \frac{w_I}{w_S}) \theta_c + (2 - \theta_w) \theta_w \frac{w_I}{w_S} \right) p_I + (2\theta_w - \theta_w^2 - \theta_c) \frac{w_I}{w_S} p_I^2 \right) \omega^2 \gamma \right), \\ b_3 &= 2 \frac{w_I}{w_S} (\omega + \gamma) \gamma \left((\omega + \gamma + \omega p_I) (2 - \theta_w) \gamma \theta_w + (1 - \theta_w) \omega^2 p_I \theta_c + \omega^2 p_I \theta_w \right), \\ c_3 &= (\omega + \gamma)^2 \gamma \left((2 - \theta_w) \gamma^2 \theta_w + \left(1 + \frac{w_I}{w_S} \right) \omega \gamma \theta_w + \frac{w_I}{w_S} \omega^2 p_I \theta_c \right), \\ d_3 &= \frac{(\omega + \gamma)}{\omega} \left((\omega p_I + \gamma) \frac{w_I}{w_S} \phi + (\omega + \gamma) \gamma \right)^2 (\omega + \phi)^2. \end{aligned} \quad (\text{A21})$$

Note that $\phi \geq 0$, also b_3 , c_3 and d_3 are all positive. However a_3 can be positive or negative. If $a_3 \geq 0$, $\partial \Delta / \partial \phi \geq 0$ for all feasible range of parameters, thus $\frac{\partial \mathcal{R}_0}{\partial \rho} \leq 0$. It is straight forward to show that $a_3 \geq 0$ in case of random testing strategy, i.e., $w_S = w_I = 1$. If $a_3 < 0$, then the quadratic expression in the numerator of (A20) has a positive root, ϕ^* , such that for $\phi > \phi^*$, $\partial \Delta / \partial \phi < 0$.

An example of this countervailing effect of ϕ , and consequently ρ , on \mathcal{R}_0 occurs when $\theta_w = 0$ and $\theta_c = 1$. This is illustrated in the top-right panel of the Fig. 3 panel (b), where the strength of isolation for awaiting people is the least, but the most for the confirmed cases. In this case, simplifying a_3 in Eq. (A21) gives

$$a_3 = \frac{w_I}{w_S} \omega \gamma p_I \left((\omega + \gamma) - \frac{w_I}{w_S} (\omega p_I + \gamma) \right) \propto \omega \left(1 - \frac{w_I}{w_S} p_I \right) + \gamma \left(1 - \frac{w_I}{w_S} \right). \quad (\text{A22})$$

If $p_I > 0$, then $a_3 < 0$ for sufficiently targeted testing (i.e. when $\frac{w_I}{w_S} p_I > 1$; because $p_I \leq 1$, $\frac{w_I}{w_S}$ is always $\geq \frac{w_I}{w_S} p_I$). When the test is perfectly sensitive ($p_I = 1$), $a_3 < 0$ as long as $\frac{w_I}{w_S} > 1$. Under either of these conditions, there exists a range for ρ over which $\frac{\partial \mathcal{R}_0}{\partial \rho} \leq 0$. Note that ρ and ω have a similar mechanism in delaying people to get into I_c , thus we would expect to see the non-trivial countervailing effect of these two parameters on \mathcal{R}_0 . **[BMB: I don't understand the last sentence]**

A.3 Rate of returning tests

The third goal is to explore how changes in the rate of test return ω affect \mathcal{R}_0 . Mathematically we would like to verify the sign of $\frac{\partial \mathcal{R}_0}{\partial \omega}$, which specifically depends on $\frac{\partial \Delta}{\partial \omega}$. We use the linearization of Δ when $\rho \ll 1$ to show that there a non-monotonic relationship between \mathcal{R}_0 and ω . The linear term in the Taylor expansion of Δ when $\rho \ll 1$ is

$$\Delta = \frac{\rho}{\omega \gamma (\omega + \gamma)} \left(\frac{w_I}{w_S} \omega^2 p_I \theta_c + \left(\frac{w_I}{w_S} + 1 \right) \gamma \omega \theta_w + \gamma^2 \theta_w (2 - \theta_w) \right). \quad (\text{A23})$$

This results in

$$\frac{\partial \Delta}{\partial \omega} = \frac{\rho}{\omega^2 (\omega + \gamma)^2} \left(\left(p_I \frac{w_I}{w_S} \theta_c - \left(1 + \frac{w_I}{w_S} \right) \theta_w \right) \omega^2 - 2 \theta_w \gamma (2 - \theta_w) \omega + \theta_w \gamma^2 (\theta_w - 2) \right). \quad (\text{A24})$$

The latter expression has two roots

$$\omega_+^* = \frac{\gamma \left(-c_4 + \sqrt{c_4^2 + (a_4 - b_4)c_4} \right)}{b_4 - a_4} \quad (\text{A25})$$

$$\omega_-^* = \frac{\gamma \left(-c_4 - \sqrt{c_4^2 + (a_4 - b_4)c_4} \right)}{b_4 - a_4}, \quad (\text{A26})$$

where $a_4 = p_I \frac{w_I}{w_S} \theta_c$, $b_4 = \left(1 + \frac{w_I}{w_S} \right) \theta_w$, $c_4 = \theta_w (2 - \theta_w)$. This enables us to describe the behaviour of \mathcal{R}_0 with respect to ω in the following two cases.

- **Case I:** If $b_4 \geq a_4$, $\frac{\partial \Delta}{\partial \omega} < 0$, so \mathcal{R}_0 is always increasing with respect to ω (i.e., it is always harmful to return tests more rapidly).
- **Case II:** If $b_4 < a_4$, \mathcal{R}_0 will be decreasing with respect to ω (i.e., returning tests more rapidly is beneficial) only when $\omega > \omega_-^*$.

Note that $b_4 \geq a_4$ is characterized by

$$\left(\frac{w_I}{w_S} + 1\right)\theta_w \geq \frac{w_I}{w_S}p_I\theta_c \iff \left(\frac{w_S}{w_I} + 1\right)\frac{1}{p_I} \geq \frac{\theta_c}{\theta_w}. \quad (\text{A27})$$

We begin with a **proof of Case I**. Suppose that $b_4 \geq a_4$. If the roots of $\frac{\partial \Delta}{\partial \omega}$ are not complex, then we must have $c_4 \geq b_4 - a_4$. Note that ω_-^* must be negative since the numerator is clearly negative but the denominator is positive. Next, note that since $c_4 \geq b_4 - a_4$, the numerator of ω_+^* must also be negative, so ω_+^* is negative. Thus, in this case, $\frac{\partial \mathcal{R}_0}{\partial \omega}$ does not change sign on $(0, \infty)$. Checking the sign of A24 for arbitrarily large ω shows that it is negative (since the $(a_4 - b_4)\omega^2$ term dominates and is negative). So \mathcal{R}_0 is increasing with respect to ω on all of $(0, \infty)$.

We now turn our attention to a **proof of Case II**. Suppose that $b_4 < a_4$. It follows that ω_+^* and ω_-^* are real since $c_4 > 0 > b_4 - a_4$. Next, note that ω_-^* is positive since both the numerator and denominator are negative. On the other hand, ω_+^* is negative since the denominator is negative but the numerator is positive (because $c_4 > b_4 - a_4$). Thus, our task is to understand the sign of $\frac{\partial \Delta}{\partial \omega}$ around the root ω_-^* . Checking the sign of A24 for arbitrarily large ω shows that it is positive (since the $(a_4 - b_4)\omega^2$ term dominates and is positive). Likewise, checking the sign for values of ω close to 0 shows that it is negative. Thus, \mathcal{R}_0 is increasing with respect to ω when $\omega < \omega_-^*$, and is decreasing $\omega > \omega_-^*$.

Having presented the formal analysis, we now concern ourselves with its biological interpretations. We begin by interpreting A27, under which returning tests more rapidly is *always* harmful. Notice that the ratio $\frac{\theta_c}{\theta_w}$ is simply a measure of how much more strongly individuals self-isolate when they test positive compared to when waiting for tests. Since the rate of test return directly influences the rate at which individuals change from a waiting state to a confirmed-positive state, it is intuitive that $\frac{\theta_c}{\theta_w}$ would appear in A27. Next, note that the left-hand side increases when test sensitivity decreases and when targeting of positive individuals is poor. This is consistent with our intuition: a false negative that is returned more rapidly may encourage an infectious individual to not carefully self-isolate, thus increasing transmission. Likewise, if individuals tested are mainly susceptible (rather than infectious), then returning tests more slowly would encourage them to self-isolate for longer while awaiting test results. Having understood the role of each of the parameters in A27, a holistic interpretation of this inequality is that returning tests more slowly is helpful when the benefit of extended self-isolation (due to awaiting test results) outweighs the benefit of identifying positive cases.

Now we interpret **Case II**. In this case, \mathcal{R}_0 will have a global maximum with respect to ω at ω_-^* . Note that our model assumption that $\rho < \omega$ plays an important role here: if $\omega_-^* < \rho$, then \mathcal{R}_0 will be always decreasing with respect to ω . On the other hand, if $\rho < \omega_-^*$, then \mathcal{R}_0 will be increasing with respect to ω on (ρ, ω_-^*) and decreasing beyond that.

A.4 On Testing Rate and Numerical Singularity

In this work, we do not present any numerical solutions of the ODEs to investigate typical trajectories. However, attempting to do so quickly reveals a problem in the way the model is posed; with the scaling of testing (σ) defined as in the body of the paper (Eq. (1)), the population in the S compartments appeared to blow up when the DFE is achieved **[BMB:**

clarify??]. This occurs because once the only untested people are susceptibles, the FOI approaches $\Lambda = 0$, and the testing rate $\mathcal{T}_S \rightarrow \rho N/S_u$. Thus, the first equation of the model (A1) will become $dS_u/dt = -\rho N + \omega S_u$. Thus changes in S_u will be independent on S_u , and the decay of the S_u population becomes linear rather than exponential — allowing S_u to become negative! To avoid this problem the testing rate, σ , should be formulated such that people from the untested compartments will not be tested if they are not there. One way to fix this issue, is to consider a maximum testing rate, τ (1/day). In general, we want to test at a rate of ρ across the whole population. This won't always be possible, so we impose a maximum rate of τ per testable person and redefine $\sigma = \frac{\tau \rho N}{\tau W + \rho N}$, with the assumption that $\tau \gg \rho$. This modification of σ does not affect any of the results we have derived about the invasion of the epidemic from the DFE (i.e., results on \mathcal{R}_0 and Δ).

A.5 The effect of testing focus parameter $\frac{w_I}{w_S}$ on \mathcal{R}_0

We define $w_{IS} = \frac{w_I}{w_S}$. **[BMB: shouldn't we use this simplified notation throughout the paper??]**

$$\frac{\partial \Delta}{\partial w_{IS}} = \frac{(\omega - \rho)(\omega(\omega - \rho\theta_w) + \gamma(\omega - \rho))(\theta_w\gamma + \theta_c\omega p_I)}{(-\omega^2\gamma + \omega\gamma\rho - \gamma\rho\omega w_{IS} - \omega\gamma^2 + \gamma^2\rho - \omega^2 p_I \rho w_{IS})^2}, \quad (\text{A28})$$

which is a positive quantity. Thus, $\frac{\partial \mathcal{R}_0}{\partial w_{IS}} \leq 0$. Therefore, increasing the focus of testing on the infectious people will result in less transmission.